To assess the clinical value of double-plane transrectal ultrasonography (DPTRUS) in the diagnosis and treatment of pelvic diseases.

A retrospective analysis was performed on patients with pelvic diseases treated at Zhejiang Provincial People's Hospital from August 2022 to March 2023. The pelvic diseases were diagnosed by routine ultrasound (RUS), contrast-enhanced ultrasound (CEUS), and high-frequency ultrasound guided puncture biopsy or catheter drainage using a bi-planar transrectal probe (convex and linear array), including ultrasonic diagnosis and puncture biopsy of 173 cases of prostate disease, 4 cases of pararectal mass, and 1 case of cervical cancer, and ultrasonic diagnosis and catheter drainage of 1 case of encapsulated effusion in the uterine rectal fossa and 1 case of prostatic abscess. The accuracy, sensitivity, and specificity of RUS and CEUS in DPTRUS for the diagnosis of prostate cancer and other pelvic diseases were calculated using pathological examination results or CT enhancement results as gold standard, and the paired chi-square test was used to determine the difference between RUS and CEUS in the diagnosis of prostate cancer.

The accuracy, sensitivity, and specificity of RUS and CEUS in DPTRUS in the diagnosis of prostate cancer were 79.2%, 66.3%, and 93.8%, and 75.0%, 54.1%, and 95.8%, and there was no significant difference between them (χ²=3.20, P=0.063). The accuracy of ultrasonic diagnosis for other pelvic diseases was 100%, and all cases successfully underwent perineal ultrasound intervention.

DPTRUS can correctly diagnose pelvic diseases and perform puncture biopsy for pathological diagnosis and puncture drainage treatment under the guidance of high-frequency ultrasound, thus achieving simultaneous diagnosis and treatment.